FAQ
Log In
Tuesday 28th March 2017
News
 › 
 › 

Improved access to psoriatic arthritis treatments

17th June 2010

The National Institute for Health and Clinical Excellence (NICE) has published new guidelines to help improve access to treatments for psoriatic arthritis.

NICE has published final draft guidance on the use of etanercept (brand name Enbrel), infliximab (brand name Remicade) and adalimumab (brand name Humira), which are recommended for adults with active and progressive psoriatic arthritis, as long as certain criteria are met. In its latest guidance, NICE proposes wider access to infliximab than had originally been recommended in its draft guidance, now recommending it as an option alongside etanercept and adalimumab.

 

Share this page

Comments

There are no comments for this article, be the first to comment!


Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Article Information

Title: Improved access to psoriatic arthritis treatments
Author: Mark Nicholls
Article Id: 15172
Date Added: 17th Jun 2010

Sources

Medical News Today
Arthritis Research UK

Recent Related Articles

Brexit fears prompting EU nurses to desert the UK

Psoriatic arthritis risk linked to depression

UK needs to recruit 1.6m new care workers by 2022

Actions

Add to scrapbook
Show Comments
Add comment
Find all related articles

Tags

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2017